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microtubule during the G2/M phase of cell cycle, thereby hin-
dering the formation of a bipolar spindle during mitosis and, 
consequently, causing a mitotic catastrophe. According to the 
results of the authors’ research, one of the working mechanisms 
of oxaliplatin may be that it not only causes apoptosis by inhib-
iting the expression of survivin but also impedes the formation 
of a bipolar spindle during mitosis as survivin fails to be posi-
tioned normally in the microtubule because it is not expressed 
properly in the microtubule or the contractile ring when the 
cells have reached the interphase of the cell cycle.
  The authors’ study is considered meaningful in that it con-
tributes to an explanation of the molecular effect of oxalipla-
tin, which is used most commonly in chemotherapy for colon 
cancer. These data indicate that survivin may be a key target 
for oxaliplatin. The ability of oxaliplatin to induce different 
modes of cell death may contribute to its efficacy in treating 
colorectal cancer.
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Oxaliplatin, a third-generation platinum-derived chemother-
apeutic agent, displays a wide spectrum of antitumor activity 
[1]. Similar to other platinum drugs, its biological activity is 
due to its ability to form lethal DNA lesions, including inter-
strand DNA crosslinks and DNA–protein crosslinks [2]. Ox-
aliplatin has fewer side-effects compared to other platinum 
drugs in terms of nephrotoxicity and myelosuppression [3]. 
Clinically, oxaliplatin effectively treats colorectal cancer in 
combination with fluorouracil and leucovorin [4]. However, 
the underlying molecular responses to oxaliplatin in colorec-
tal cancer remain largely unknown. 
In the present study, the authors investigated the effect of 
oxaliplatin on one colon cancer cell line, HCT 119. They dem-
onstrated that oxaliplatin treatment inhibited the expression 
of the survivin protein and survivin mRNA in HCT116 colon 
cancer cells. The authors report that the expression of the sur-
vivin-2B variants, which have no antiapoptotic activity but 
control the cell mitosis by localization on a microtubule, was 
reduced continuously over the first two days following treat-
ment with oxaliplatin. In immunocytochemistry, expression 
of survivin in the cytoplasm was reduced and, in particular, 
survivan was not expressed in microtubules and contractile 
rings.
The authors conjecture that the reason for the continuous 
decrease of survivin-2B, which is known to have little apopto-
sis inhibition effect among the survivin variants, might have 
been that survivin-2B failed to be positioned normally in the 
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